Ascendis Pharma AS 2024 SR
The report outlines Ascendis Pharma's sustainability and Patient, Environmental, Social, and Governance (P|ESG) activities for the fiscal year 2024. Key highlights include the launch of Yorvipath in Germany and the U.S., the implementation of a pilot Double Materiality Assessment, and the reporting of Scope 1 and Scope 2 greenhouse gas emissions. The company also expanded its global workforce to over 1,000 employees and established an approved supplier list for biological matrices to support high animal welfare standards.
Company: Ascendis Pharma AS
Sector: Health Care
Country: Denmark
Year: 2024
Type: SR
Pages: 37
Ascendis Pharma AS
Sustainability And P ESG Report
The report outlines Ascendis Pharma's sustainability and Patient, Environmental, Social, and Governance (P|ESG) activities for the fiscal year 2024. Key highlights include the launch of Yorvipath in Germany and the U.S., the implementation of a pilot Double Materiality Assessment, and the reporting of Scope 1 and Scope 2 greenhouse gas emissions. The company also expanded its global workforce to over 1,000 employees and established an approved supplier list for biological matrices to support high animal welfare standards.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Women on Board
Women in Management
Workplace Fatalities
Employees